Parameter | Value (Percent/Range) |
---|---|
Median (range) age, years | 63 (35–80) |
Gender | |
Male | 23 (60.5%) |
Female | 15 (39.5%) |
ECOG performance status | |
0 | 13 (34.2%) |
1 | 20 (52.6%) |
2 | 5 (13.2%) |
3 | 0 (0%) |
History of chronic kidney disease | |
Yes | 0 (0%) |
No | 38 (100%) |
Nephroaffective medication at diagnosis | |
Metformin | 6 (16%) |
ACE inhibitors | 3 (8%) |
Median (range) tumor size, cm | 3.0 (0.8–6.5) |
Resectability status | |
Borderline resectable | 13 (34.2%) |
Unresectable | 25 (65.8%) |
Median (range) pre-SBRT creatinine, mg/dL | 0.8 (0.5–1.4) |
Median (range) pre-SBRT GFR, mL/min/1.73 m2 | 96.8 (50.1–142.0) |
Median (range) post-SBRT creatinine peak, mg/dL | 1.1 (0.5–3.57) |
Median (range) pre-SBRT GFR nadir, mL/min/1.73 m2 | 61.6 (12.9–147.7) |
Median (range) contoured volume of kidneys, cm3 | 355 (187–726) |
Median (range) PTV volume, cm3 | 130 (59–275) |
SBRT technique | |
Fixed-beam | 36 (94.7%) |
Arc | 2 (5.3%) |
Receipt of pancreaticoduodenectomy | |
Yes | 10 (26.3%) |
No | 28 (73.7%) |